I agree with you as well. However, you will be disappointed if you are counting on big pharma to get involved in the next year or two. Until recently, I thought big pharma was lurking around as well and thats what was driving their non action around hiring and reimbursements when they are sitting on the cusp of approval in the UK.
But it’s increasingly clear now that no big pharma is interested in this company and management via its social media army will continue to kick the can as usual. First it will be Flaskworks and when that does not go according to plan for another year or two, then the attention will be deflected towards Direct. All this while they can’t even get reimbursement in the UK or approvals from other jurisdictions for L. There will be no support or marketing blitz from the UK media after approval either. These guys just do not have the right skill set, team, and the backing from big players. It should have been clear by now.
For instance, if they did plan on applying to EU or Canada (forget about US) they would have done it by now or would do it as soon as they get UK approval notice. If they cant submit those applications (at least EU and Canada) in 4 years then something is terribly wrong. Forget about reimbursement in any jurisdiction. Why would any investment firm or big pharma treat them seriously if they cant execute in a reasonable way what’s in their control?
I’d watch for these signs and not remain a bagholder when we do get a spike at UK approval because there will be limited to no major milestones for another year or so.
Market Data 
Markets 
AI
